Talk:Adrenocorticotropic hormone (medication)
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Adrenocorticotropic hormone (medication).
|
| This is the talk page for discussing improvements to the Adrenocorticotropic hormone (medication) article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated B-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | The contents of the Tetracosactide page were merged into Adrenocorticotropic hormone (medication). For the contribution history and old versions of the redirected page, please see its history; for the discussion at that location, see its talk page. |
JAMA Internal Medicine 2017
editThis article discusses the high cost and lack of evidence for many indications.
http://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2653010 Trends and Characteristics of US Medicare Spending on Repository Corticotropin Daniel M. Hartung, PharmD, MPH; Kirbee Johnston, MPH; Shelby Van Leuven; et al. JAMA Intern Med. September 11, 2017. doi:10.1001/jamainternmed.2017.3631
This study uses Medicare Drug Spending Dashboard data to estimate the cost of repository corticotropin to the Medicare program and assess its within-specialty prescribing patterns.
Repository corticotropin (rACTH) injection (H. P. Acthar gel; Mallinckrodt Pharmaceuticals) has been under intense scrutiny for its very high cost.1,2 Because rACTH is approved for a variety of immunologic conditions prevalent in the US Medicare population, prescriptions for rACTH may have a significant financial impact on Medicare expenditures. The objectives of this study were to (1) estimate the cost of rACTH to the Medicare program, and (2) assess the within-specialty prescribing patterns for this medication.
Move discussion in progress
editThere is a move discussion in progress on Talk:Lithium (medication) which affects this page. Please participate on that page and not in this talk page section. Thank you. —RMCD bot 23:15, 28 January 2019 (UTC)